Paris, France — August 27, 2025 — Leads & Copy — Nanobiotix SA (Nasdaq: NBTX) disclosed its voting rights and share capital as of July 31, 2025, in accordance with French regulations. The company has 48,236,671 shares outstanding. The total number of voting rights is 50,340,736, with 50,318,618 exercisable.
Nanobiotix, incorporated in 2003, focuses on physics-based therapeutic approaches. Listed on Euronext Paris since 2012 and Nasdaq since December 2020, the company holds patents for nanotechnology platforms in oncology, bioavailability, biodistribution, and central nervous system disorders.
Brandon Owens, VP, Communications, +1 (617) 852-4835, contact@nanobiotix.com; Joanne Choi, VP, Investor Relations (US), +1 (713) 609-3150; Ricky Bhajun, Director, Investor Relations (EU), investors@nanobiotix.com; Caroline Hardy, HARDY, +33 06 70 33 49 50, carolinehardy@outlook.fr; Becky Lauer, uncapped, +1 (646) 286-0057, uncappednanobiotix@uncappedcommunications.com
Source: Nanobiotix
